Comparative Pharmacology
Head-to-head clinical analysis: DELFLEX W DEXTROSE 1 5 LOW MAGNESIUM IN PLASTIC CONTAINER versus DELFLEX W DEXTROSE 2 5 LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELFLEX W DEXTROSE 1 5 LOW MAGNESIUM IN PLASTIC CONTAINER versus DELFLEX W DEXTROSE 2 5 LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER.
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER vs DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Peritoneal dialysis solution; dextrose provides osmotic gradient for ultrafiltration and solute removal; low magnesium formulation reduces magnesium accumulation in renal failure patients.
Peritoneal dialysis solution; dextrose provides osmotic gradient for ultrafiltration and solute removal; low magnesium and low calcium concentrations maintain electrolyte balance.
Intraperitoneal administration: 2 liters per exchange, 4 exchanges per day; dextrose concentration and fill volume adjusted based on ultrafiltration needs.
Intraperitoneal: 2.5% dextrose solution with low magnesium (0.25 mEq/L) and low calcium (2.5 mEq/L); typical exchange volume 2-2.5 L per exchange, 4-5 exchanges per day for continuous ambulatory peritoneal dialysis.
None Documented
None Documented
Terminal elimination half-life not applicable; drug effects persist as long as solution remains in peritoneal cavity (dwell time 4–8 hours for CAPD).
Dextrose: 1.5–2 hours (intracellular metabolism); Magnesium: 27–40 hours; Calcium: 2.5–3 hours (exchangeable pool); Low concentrations do not alter endogenous kinetics.
Renal: 99% (as glucose and electrolytes), biliary/fecal: <1%
Renal: 100% (unchanged dextrose and electrolytes; magnesium and calcium are partially reabsorbed, but net excretion is via urine). Biliary/fecal: negligible.
Category C
Category C
Peritoneal dialysis solution
Peritoneal dialysis solution